Derya Unutmaz

Biosketch / Results /

Derya Unutmaz

Adjunct Professor, Department of Microbiology

Contact Info

Address
522 First Avenue
New York, NY 10016

212/263-9203
Derya.Unutmaz@nyumc.org


Bioprinting towards Physiologically Relevant Tissue Models for Pharmaceutics
Peng, Weijie; Unutmaz, Derya; Ozbolat, Ibrahim T. Bioprinting towards Physiologically Relevant Tissue Models for Pharmaceutics. Trends in biotechnology. 2016 Sep;34(9):722-732 (2179762)

FOXP3+Helios+ regulatory T cells, immune activation and advancing disease in HIV infected children
Khaitan, Alka; Kravietz, Adam; Mwamzuka, Mussa; Marshed, Fatma; Ilmet, Tiina; Said, Swalehe; Ahmed, Aabid; Borkowsky, William; Unutmaz, Derya. FOXP3+Helios+ regulatory T cells, immune activation and advancing disease in HIV infected children. Journal of acquired immune deficiency syndromes. JAIDS. 2016 Aug 15;72(5):474-484 (2059662)

Hodgkin lymphoma patients demonstrate evidence of chronic activation/exhaustion in circulating T cell subsets
Diefenbach, Catherine S; Raphael, Bruce; Hymes, Kenneth; Grossbard, Michael; Moskovits, Tibor; Kaminetzky, David; Mcshea, Meghan; Martin, Peter; Ruan, Jia; Kozhaya, Lina; Bonakdar, Maryann; Abidoglu, Cem; Leonard, John; Unutmaz, Derya. Hodgkin lymphoma patients demonstrate evidence of chronic activation/exhaustion in circulating T cell subsets [Meeting Abstract]. Cancer research. 2016 JUL;76:?-? (2411312)

Store-Operated Ca Entry in Follicular T Cells Controls Humoral Immune Responses and Autoimmunity
Vaeth, Martin; Eckstein, Miriam; Shaw, Patrick J; Kozhaya, Lina; Yang, Jun; Berberich-Siebelt, Friederike; Clancy, Robert; Unutmaz, Derya; Feske, Stefan. Store-Operated Ca Entry in Follicular T Cells Controls Humoral Immune Responses and Autoimmunity. Immunity. 2016 Jun 21;44(6):1350-1364 (2125342)

Phase II trial of exemestane with immunomodulatory oral cyclophosphamide in metastatic hormone receptor (HR)-positive breast cancer: Prolonged progression-free survival (PFS) in patients with distinct T regulatory cell (Treg) profile
Kwa, M; Novik, Y; Oratz, R; Jhaveri, K; Wu, J; Gu, P; Meyers, M; Muggia, F; Bonakdar, M; Abidoglu, C; Kozhaya, L; Li, X; Joseph, B; Iwano, A; Friedman, K; Goldberg, JD; Unutmaz, D; Adams, S. Phase II trial of exemestane with immunomodulatory oral cyclophosphamide in metastatic hormone receptor (HR)-positive breast cancer: Prolonged progression-free survival (PFS) in patients with distinct T regulatory cell (Treg) profile [Meeting Abstract]. Cancer research. 2016 FEB 15;76:?-? (2411072)